Safety
thrombocytopenia, nausea/ vomiting, neutropenia, anemia
ADVERSE EVENTS, THROMBOCYTOPENIA, NEUTROPENIA, ANEMIA
Treatment-related adverse events (TRAE) were documented for all 18 enrolled patients. The most common (observed in >15% of patients) grade ≥ 3 triplet regimen TRAEs included neutropenia (40%), nausea/ vomiting (27%), thrombocytopenia (20%), and anemia (20%, Ulixertinib treatment related adverse events (TRAE) of enrolled patients (